Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-80948543
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
JNJ-80948543 is a fully human immunoglobulin G1 (IgG1) T-cell redirecting trispecific antibody developed for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It targets CD79b and CD20 antigens on tumor B-cells and the CD3 antigen on T-cells. By binding to these targets, it redirects and activates T-cells to recognize and kill malignant B-cells. The drug is being investigated in combination with other agents such as the bispecific antibody JNJ-75348780 in early-phase clinical trials[1][2][3][4][5][6][7].
- Other names
- anti-CD79b/CD20/CD3 trispecific antibody
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chain
Beyond the preview
Go deeper on JNJ-80948543.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-80948543.